

Walther et al. 2024. DOI: <https://doi.org/10.1530/eor-23-0075>


Operative management of osteochondral lesions of the talus: 2024 recommendations of the working group ‘clinical tissue regeneration’ of the German Society of Orthopedics and Traumatology (DGOU)

Methodology

- Additional evidence updates initial 2017 recommendations for osteochondral lesions of the talus (OLT).
- A subgroup of 29 foot and ankle surgeons reviewed the literature on different topics relevant to OLT treatment, concluded with a statement for each topic and made a recommendation. Statements were evaluated to identify potential gaps between clinical experience and evidence. The new guidelines represent the best evidence available in 2023 for OLT treatment.

Surgical treatment algorithm for OLT

- In chronic OLT, malalignment and instability, if present, must be corrected before any cartilage treatment.
- The additional use of a scaffold with bone marrow stimulation (M-BMS) is recommended to stabilize the bone graft in cystic OLT.
- Early studies supported the benefit of M-BMS in larger lesions (> 1.5 cm²) compared to microfracture alone.
- Based on the available evidence, the critical cutoff for M-BMS seems closer to 1.0 cm² than 1.5 cm².



Fact

”While there is a paucity of clinical data for most scaffolds used in M-BMS, the **preponderance of data** for **Chondro-Gide®**, as measured by the volume of peer-reviewed literature, supports its role as an **essential element** in treating **OLT**.”



Chondro-Gide®
Literature Highlight

This literature highlight addresses important aspects of the evidence for the use of Chondro-Gide®.

XPERIENCE THE EVIDENCE

100+ peer-reviewed
publications



Manage
OLT with
AMIC®!

AMIC® Chondro-Gide®

- Combines bone marrow stimulating techniques with the collagen membrane¹
- Biocompatible and naturally resorbed membrane¹
- Easy to handle, supple and tear-resistant²
- Compatible with a range of cost-efficient, one-step cartilage regenerative techniques^{2,3,4}
- Stable results over 10+ years⁵



More details about
our products and
distribution partners:



Geistlich Pharma AG
Bahnhofstrasse 40
6110 Wollhusen
Switzerland
ortho@geistlich.com
www.geistlich-ortho.com

- 1 Geistlich Pharma AG, data on file (bench tests and pre-clinical studies)
- 2 Kramer J, et al., Cell Mol Life Sci. 2006 Mar;63(5):616-26. (Clinical study)
- 3 Walther M, et al., Oper Orthop Traumatol. 2014 Dec;26(6):603-10. (Clinical study)
- 4 Fossum V, et al., Orthop J Sports Med. 2019 Sep;7(9):2325967119868212. (Clinical study)
- 5 Kaiser N, et al., Arch Orthop Trauma Surg. 2021 Nov;141(11):1845-54. (Clinical study)